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a mammal having a Zika virus ( ZIKV ) infection . For 
example , a composition including one or more non - nucleo 
side RNA polymerase inhibitors can be administered to a 
mammal having , or at risk of developing , a ZIKV infection 
to treat the mammal 
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METHODS OF TREATING OR PREVENTING 
ZIKA VIRUS INFECTION 
CROSS - REFERENCE TO RELATED 
APPLICATIONS 
[ 0001 ] This application is a continuation application of 
U.S. patent application Ser . No. 16 / 176,846 , filed Oct. 31 , 
2018 , which claims the benefit of U.S. Patent Application 
Ser . No. 62 / 579,495 , filed on Oct. 31 , 2017. The disclosure 
of the prior applications are considered part of ( and are 
incorporated by reference in ) the disclosure of this applica 
tion . 
BACKGROUND 
1. Technical Field 
[ 0002 ] This document relates to methods and materials for 
treating a mammal having a Zika virus ( ZIKV ) infection . 
For example , one or more non - nucleoside RNA polymerase 
inhibitors can be administered a mammal having , or at 
risk of developing , a ZIKV infection to treat the mammal . 
2. Background Information 
[ 0003 ] ZIKV , a mosquito - borne pathogen , was originally 
isolated in Uganda in 1947 ( Dick et al . , 1952 Trans . Roy . 
Soc . Trop . Med . Hyg . 46 : 509-520 ) and only sporadic cases 
of virus outbreaks in humans were reported in Africa and 
Asia in the next six decades ( Mecharles et al . , 2016 Lancet 
387 : 1481 ; Munoz et al . , 2016 Semin . Reprod . Med . 34 : 273 
279 ) . However , in the past ten years , it has rapidly emerged 
and spread to the regions of Asia , Europe , and the Americas 
( Aliota et al . , 2017 Antivir . Res . 144 : 223-246 ; Chan et al . , 
2016 J. Infect . 72 : 507-524 ; Deseda , 2017 Curr . Opin . Pedi 
atr . 29 : 97-101 ; Weaver et al . , 2016 Antivir . Res . 130 : 69-80 ) . 
Although the majority of infections in humans are asymp 
tomatic , recent ZIKV infections have been linked to a 
variety of congenital disorders including microcephaly and 
fetal growth restriction ( Carteaux et al . , 2016 N. Engl . J. 
Med . 374 : 1595-1596 .; Cauchemez et al . , 2016 Lancet 387 : 
2125-2132 ; Chan et al . , 2016 J. Infect . 72 : 507-524 ; Coyne 
and Lazear , 2016 Nat . Rev. Microbiol . 14 : 707-715 ; Cugola 
et al . , 2016 Nature 534 : 267-271 ; Lazear and Diamond , 2016 
J. Virol . 90 : 4864-4875 ; Miner and Diamond , 2017 Cell Host 
Microbe 21 : 134-142 ; and Mlakar et al . , 2016 N. Engl . J. 
Med . 374 : 951-958 ) as well as Guillain - Barre syndrome in 
adults ( Avelino - Silva and Martin , 2016 Lancet 387 : 2599 ; 
Nascimento et al . , 2017 Neurology 88 : 2330-2332 ; and Parra 
et al . , 2016 N. Engl . J. Med . 375 : 1513-1523 ) . These severe 
consequences and the large - scale spreading of the virus have 
imposed a significant threat to human health worldwide 
( Fauci and Morens , 2016 N. Engl . J. Med . 374 : 601-604 ; 
Gulland , 2016 BMJ 352 : 1657 ; Roos , 2016 J. Neurol . 
73 : 1395-1396 ) . So far , no vaccine or drug for preventing or 
treating this viral disease is available ( Shan et al . , 2016 Adv . 
Infect . Dis . 2 : 170-172 ) . Therefore , it is urgent to develop 
countermeasures against this viral epidemic ( Rather et al . , 
2017 Front . Microbiol . 8 : 305 ; Salam et al . , 2017 Ann . 
Intern . Med . 166 : 725-732 ) . 
[ 0005 ] This document provides methods and materials for 
treating a mammal having , or at risk of developing , ZIKV in 
its bloodstream ( e.g. , ZIKV viremia ) . In some cases , ZIKV 
viremia can lead to a ZIKV infection . For example , one or 
more non - nucleoside RNA polymerase inhibitors ( e.g. , 
3 - chloro - N - [ ( { 4- [ 4- ( 2 - thienylcarbonyl ) -1 - piperazinyl ] 
phenyl } amino ) carbonothioyl ] -1 - benzothiophene - 2 - carbox 
amide ( TPB ) ) can be administered to a mammal having , or 
at risk of developing , ZIKV viremia to treat the mammal . In 
some cases , one or more non - nucleoside RNA polymerase 
inhibitors can inhibit ZIKV replication ( e.g. , within in a cell 
in a mammal ) . In some cases , one or more non - nucleoside 
RNA polymerase inhibitors can reduce ZIKV viremia in a 
mammal . 
[ 0006 ] As demonstrated herein , TPB inhibited ZIKV rep 
lication at sub - micromolar concentrations ( e.g. , the half 
maximal inhibitory concentration ( IC50 ) and the cytotoxicity 
concentration ( CC50 ) of TPB in Vero cells were 94 nM and 
19.4 uM , respectively , yielding a high selective index 50 
( SI50 ) of 206 ) . Without being bound by theory , molecular 
docking analysis suggested that TPB binds to the catalytic 
active site of the ZIKV RNA - dependent RNA - polymerase 
( RdRp ) and therefore likely blocks the viral RNA synthesis 
by an allosteric effect . Also as demonstrated herein , TPB 
reduced ZIKV viremia significantly in immunocompetent 
mice . The ability to inhibit ZIKV replication can reduce 
ZIKV viremia providing a unique and unrealized opportu 
nity to treat and / or prevent ZIKV infections . For example , 
TPB can be used to treat and / or prevent ZIKV infections . 
[ 0007 ] In general , one aspect of this document features 
methods for treating mammals having a ZIKV infection . The 
methods can include , or consist essentially of , administering 
to a composition including a non - nucleoside RNA poly 
merase inhibitor to a mammal having a ZIKV infection to 
treat the mammal . The mammal can be a human . The 
non - nucleoside RNA polymerase inhibitor can bind to a 
catalytic active site of an RdRp of a ZIKV to inhibit ZIKV 
replication . The non - nucleoside RNA polymerase inhibitor 
can be TPB . The non - nucleoside RNA polymerase inhibitor 
can have an IC50 of from about 10 nM to about 200 nM . The 
non - nucleoside RNA polymerase inhibitor can have a CC50 
of from about 15 uM to about 25 uM . The non - nucleoside 
RNA polymerase inhibitor can have a Slso of about 206. The 
administering step can be performed prior to the mammal 
being infected with the ZIKV or after the mammal being 
infected with the ZIKV . The administering step can be 
performed prior to the mammal being infected with the 
ZIKV and after the mammal being infected with the ZIKV . 
The non - nucleoside RNA polymerase inhibitor can be 
administered intraperitoneally , intravenously , intramuscu 
larly , or subcutaneously . 
[ 0008 ] In another aspect , this document features methods 
for method of preventing microcephaly in a fetus . The 
methods can include , or consist essentially of , administering 
a composition including a non - nucleoside RNA polymerase 
inhibitor to a mammal pregnant with a fetus , where the 
pregnant mammal has a ZIKV infection . The mammal can 
be a human . The non - nucleoside RNA polymerase inhibitor 
can bind to a catalytic active site of an RdRp of a ZIKV to 
inhibit ZIKV replication . The non - nucleoside RNA poly 
merase inhibitor can be TPB . The non - nucleoside RNA 
polymerase inhibitor can have an IC50 of from about 10 nM 
to about 200 nM . The non - nucleoside RNA polymerase 
inhibitor can have a CC 50 of from about 15 uM to about 25 
SUMMARY 
[ 0004 ] ZIKV has become a major human health concern 
globally due to its association with congenital abnormalities 
and neurological diseases . 
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uM . The non - nucleoside RNA polymerase inhibitor can 
have a SI5 , of about 206. The non - nucleoside RNA poly 
merase inhibitor can be administered intraperitoneally , intra 
venously , intramuscularly , or subcutaneously . 
[ 0009 ] In another aspect , this document features methods 
for treating adult mammals having Guillain - Barre syn 
drome . The methods can include , or consist essentially of ,
administering a composition including a non - nucleoside 
RNA polymerase inhibitor to a mammal having a ZIKV 
infection and having Guillain - Barre syndrome to treat the 
mammal . The mammal can be a human . The non - nucleoside 
RNA polymerase inhibitor can bind to a catalytic active site 
of an RdRp of a ZIKV to inhibit ZIKV replication . The 
non - nucleoside RNA polymerase inhibitor can be TPB . The 
non - nucleoside RNA polymerase inhibitor can have an IC50 
of from about 10 nM to about 200 nM . The non - nucleoside 
RNA polymerase inhibitor can have a CC50 of from about 15 
uM to about 25 ?M . The non - nucleoside RNA polymerase 
inhibitor can have a SI50 of about 206. The non - nucleoside 
RNA polymerase inhibitor can be administered intraperito 
neally , intravenously , intramuscularly , or subcutaneously . 
[ 0010 ] In another aspect , this document features compo 
sitions for reducing ZIKV viremia within a mammal . The 
compositions include a non - nucleoside RNA polymerase 
inhibitor . The non - nucleoside RNA polymerase inhibitor can 
be TPB . The non - nucleoside RNA polymerase inhibitor can 
bind to a catalytic active site of an an RdRp of a ZIKV . The 
non - nucleoside RNA polymerase inhibitor can have an IC50 
of from about 10 nM to about 200 nM . The non - nucleoside 
RNA polymerase inhibitor can have a CC50 of from about 15 
uM to about 25 uM . The non - nucleoside RNA polymerase 
inhibitor can have a S150 of about 206. The composition also 
can include a pharmaceutically acceptable carrier . 
[ 0011 ] Unless otherwise defined , all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention pertains . Although methods and materials similar 
or equivalent to those described herein can be used to 
practice the invention , suitable methods and materials are 
described below . All publications , patent applications , pat 
ents , and other references mentioned herein are incorporated 
by reference in their entirety . In case of conflict , the present 
specification , including definitions , will control . In addition , 
the materials , methods , and examples are illustrative only 
and not intended to be limiting . 
[ 0012 ] The details of one or more embodiments of the 
invention are set forth in the accompanying drawings and 
the description below . Other features , objects , and advan 
tages of the invention will be apparent from the description 
and drawings , and from the claims . 
filing model of the boxed area in A is shown along with the 
bound TPB . TPB binding at the palm subdomain is shown . 
[ 0014 ] FIGS . 2A - 2B show inhibition of ZIKV replication 
by the top 10 lead compounds . ( FIG . 2A ) Viral genome 
copies in the supernatants of cells infected with PRVABC59 
virus in the presence of 1 um concentration of the ten 
compounds ( cl - c10 ) or with vehicle ( DMSO ) alone for 72 
hours . The data are expressed as % of DMSO - treated 
control . The experiment was done in triplicate and bars 
represent : SEM . ( FIG . 2B ) Infectious virus titers in the 
supernatant of cells infected with the virus and incubated 
with 1 uM concentration of the compounds or with vehicle 
( DMSO ) alone for 96 hours . 
[ 0015 ] FIGS . 3A - 3C show validation of the antiviral effect 
of TPB in the uM range . ( FIG . 3A ) Cells infected with 
PRVABC59 virus were incubated in the presence of various 
concentrations of TPB for 96 hours . Culture supernatants 
were titrated for viral genome copies ( FIG . 3A ) and infec 
tious virus ( FIG . 3B ) . Data are from three independent 
experiments with error bars showing + SEM . Statistical 
analysis was performed using unpaired two - tailed Student's 
t - test to determine significance of difference . p = 0.001 . 
( FIG . 3C ) Western blot analysis of E protein expression in 
virus - infected cells in the presence of various concentrations 
of TPB . Relative mobility of molecular mass markers are 
shown on the left . 
[ 0016 ] FIGS . 4A - 4C shows TPB inhibition of ZIKV is 
strain and cell - type independent . ( FIG . 4A ) Inhibition of 
MR766 virus by TPB . The experiments were conducted as 
in FIG . 3B and data from three independent experiments are 
presented with error bars representing SEM . PRVABC59 
virus growth in HTR - 8 ( FIG . 4B ) and NTERRA ( FIG . 4C ) 
cell lines in the presence of TPB . Data from three indepen 
dent experiments are presented with error bars showing 
SEM . Statistical analysis was performed using unpaired 
two - tailed Student's t - test to determine significance of dif 
ference . **** , p < 0.001 . 
[ 0017 ] FIGS . 5A - 5B show IC50 and CC50 of TBP . ( FIG . 
5A ) Vero cells in triplicate were infected with PRVABC59 
virus and incubated with various concentrations of TPB as 
shown . Infectious virus titers in the supernatants of the cells 
at 96 hours post - infection were determined by plaque assay 
and virus yield was expressed as % of TPB - untreated 
control . Non - linear regression analysis was employed to 
determine the IC50 . ( FIG . 5B ) Vero cells in triplicate were 
treated with TPB at various concentrations for four days and 
cell viability was measured based on ATP assay . The lumi 
nescence signals were measured at 420 nm using a 
Microplate Luminometer . Non - linear regression analysis of 
the data was employed to determine the CC50 . 
[ 0018 ] FIG . 6 shows a comparison of TPB inhibitory 
activity with mycophenolic acid ( MPA ) and Ivermectin 
( IVM ) . Vero cells were infected with PRVABC59 virus and 
incubated with TPB ( 1 uM ) , MPA ( 1 uM ) and IVM ( 10 uM ) . 
Culture supernatants were collected at 96 hours post - infec 
tion and assayed for infectious virus . Data presented are 
from three independent experiments with error bars showing 
SEM . Statistical analysis was performed using unpaired 
two - tailed Student's t - test to determine significance of dif 
ference . *** p < 0.01 ; **** p < 0.001 . 
[ 0019 ] FIGS . 7A - 7D shows inhibitory efficacy of TPB in 
mice . ( FIG . 7A ) Pharmacokinetics ( PK ) analysis of TPB in 
mice using two different doses as shown . ( FIG . 7B ) Genome 
copies at various days post - infection in the plasma of 
DESCRIPTION OF THE DRAWINGS 
[ 0013 ] FIGS . 1A - 1D show a structure - based screening of 
inhibitors of ZIKV targeting the viral RNA - dependent 
RNA - polymerase ( RdRp ) . ( FIG . 1A ) Structure of ZIKV 
RdRp generated by homology modeling . The three subdo 
mains are colored individually , Fingers ( cyan ) , Thumb 
( blue ) and Palm ( red ) . The catalytic active site and the 
priming loop are labeled . Docking of TPB on the active site 
of RdRp and the contacts with the two aspartic residues 
( D535 and D665 ) along with the three hydrogen bonds are 
indicated . ( FIG . 1B ) The chemical structure of TPB ( mo 
lecular weight of 541.108 ) . ( FIG . 1C ) A larger view of the 
boxed area in A is shown for clarity . ( FIG . 1D ) The space 
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individual mice treated without ( continuous lines ) or with 
( discontinuous lines ) TPB . ( FIG . 7C ) Data from the mice 
groups in panel B. Error bars show ESEM . Statistical 
analysis was performed using unpaired two - tailed Student's 
t - test to determine significance of difference . **** ps0.001 . 
( FIG . 7D ) TPB mean concentrations in mice plasma at 
various days post - infection . Error bars show + SEM . 
[ 0020 ] FIG . 8 shows model of superimposed structures of 
ZIKV RdRp . Cyan , RdRp structure derived from homology 
modeling ; yellow , crystal structure of RdRp ( PDB : 5WZ3 ) . 
Various domains are identified . 
[ 0021 ] FIGS . 9A - 9B shows models of an alignment of 
compounds within the target site of the ZIKV RdRp ( FIG . 
9A ) and an enlarged view of the positioning of the com 
pounds ( FIG . 9B ) in the target site of the RdRp . 
[ 0022 ] FIG . 10 contains exemplary non - nucleoside RNA 
polymerase inhibitors . 
DETAILED DESCRIPTION 
[ 0023 ] This document provides methods and materials for 
treating a mammal having , or at risk of developing ZIKV 
viremia ( e.g. , a ZIKV infection ) . In some cases , this docu ment provides compositions ( e.g. , pharmaceutical composi 
tions such as vaccines ) including one or more non - nucleo 
side RNA polymerase inhibitors ( e.g. , TPB ) . In some cases , 
this document provides methods for using one or more 
non - nucleoside RNA polymerase inhibitors provided herein 
to treat a mammal having , or at risk of having , a ZIKV 
infection . For example , one or more non - nucleoside RNA 
polymerase inhibitors can be administered to a mammal 
( e.g. , a human ) having , or at risk of developing , a ZIKV 
infection to treat the mammal . In some cases , one or more 
non - nucleoside RNA polymerase inhibitors can inhibit 
ZIKV replication ( e.g. , within in a cell in a mammal ) . In 
some cases , one or more non - nucleoside RNA polymerase 
inhibitors can reduce ZIKV viremia in a mammal . One or 
more non - nucleoside RNA polymerase inhibitors can be 
administered to a mammal to protect the mammal from a 
ZIKV infection ( e.g. , prior to exposure to a ZIKV ) and / or to 
treat the mammal ( e.g. , after exposure to a ZIKV ) . 
[ 0024 ] Any appropriate mammal ( e.g. , a mammal having , 
or at risk of developing , ZIKV viremia ) can be treated as 
described herein . In some cases , a mammal can have , or can 
be at risk of developing , a ZIKV infection . In some cases , a 
mammal can carry ZIKV without developing ZIKV infec 
tion . Examples of mammals that can be treated as described 
herein ( e.g. , by administering one or more non - nucleoside 
RNA polymerase inhibitors such as TPB to the mammal ) 
include , without limitation , humans , non - human primates 
( e.g. , monkeys ) , dogs , cats , horses , cows , pigs , sheep , mice , 
rats , horses , cows , carabaos ( water buffaloes ) , goats , ducks , 
and bats . For example , a human having , or at risk of 
developing , ZIKV viremia can be treated by administering 
one or more non - nucleoside RNA polymerase inhibitors 
( e.g. , TPB ) to that human . In some cases , a mammal can be 
a pregnant mammal ( e.g. , pregnant human ) . When a mam 
mal is a pregnant human , the pregnant human can be in any 
stage of pregnancy ( e.g. , first trimester , second trimester , or 
third trimester ) . 
[ 0025 ] When treating a mammal ( e.g. , a human ) having , or 
at risk of developing , ZIKV viremia ( e.g. , a ZIKV infection ) 
as described herein ( e.g. , by administering one or more 
non - nucleoside RNA polymerase inhibitors such as TPB to 
the mammal ) , the mammal can be any appropriate age . In 
some cases , a mammal can be an adult . For example , when 
a mammal is a human , an adult human can be about 18 years 
of age or older ( e.g. , about 20 years of age , about 30 years 
of age , about 40 years of age , about 50 years of age , about 
60 years of age , about 65 years of age , about 70 years of age , 
or about 75 years of age or older ) . For example , when a 
mammal is a human , an adult human can be from about 18 
years of age to about 80 years of age ( e.g. , from about 18 
years of age to about 60 years of age , from about 18 years 
of age to about 40 years of age , from about 25 years of age 
to about 80 years of age , from about 40 years of age to about 
80 years of age , from about 60 years of age to about 80 years 
of age , from about 20 years of age to about 60 years of age , 
or from about 30 years of age to about 50 years of age ) . In 
some cases , a mammal can be a juvenile . For example , when 
a mammal is a human , a juvenile human can be no more than 
about 18 years old . For example , a human adolescents can 
be from about 1 year of age to about 18 years of age ( e.g. , 
from about 1 year of age to about 15 years of age , from about 
1 year of age to about 10 years of age , from about 1 year of 
age to about 5 years of age , from about 5 years of age to 
about 18 years of age , from about 10 years of age to about 
18 years of age , or from about 5 years of age to about 15 
years of age ) . In some cases , a mammal can be a newborn . 
For example , when a mammal is a human , a newborn human 
from about birth to about 1 year of age . In some cases , a 
mammal can be a fetus . For example , when a mammal is a 
human , a fetus can be in utero ( e.g. , being carried by a 
human pregnant with the fetus ) . 
[ 0026 ] When treating a mammal ( e.g. , a human ) having , or 
at risk of developing , ZIKV viremia ( e.g. , a ZIKV infection ) 
as described herein ( e.g. , by administering one or more 
non - nucleoside RNA polymerase inhibitors such as TPB to 
the mammal ) , the ZIKV can be any type of ZIKV . A ZIKV 
can be from any lineage of ZIKV . A ZIKV can be from any 
clade of ZIKV . A ZIKV can be any strain of ZIKV . In some 
cases , a ZIKV can be a latent ZIKV . In some cases , a ZIKV 
can be an infectious ZIKV . Examples of ZIKVs include , 
without limitation , East African ZIKV , West African ZIKV , 
Asian ZIKV , and South American ZIKV . 
[ 0027 ] In some cases , methods described herein can 
include identifying a mammal ( e.g. , a human ) as having a 
ZIKV infection . Any appropriate method can be used to 
identify a mammal having a ZIKV infection . For example , 
the presence of a ZIKV in a sample obtained from a mammal 
can be detected in a sample obtained from a mammal , where 
the presence of a ZIKV can indicate that the mammal has a 
ZIKV infection . In some cases , the presence of a ZIKV 
genome , or a portion thereof , in a sample obtained from a 
mammal can be used to identify that mammal ( e.g. , a 
human ) as having a ZIKV infection . In some cases , the 
presence of one or more ZIKV polypeptides in a sample 
obtained from a mammal can be used to identify that 
mammal ( e.g. , a human ) as having a ZIKV infection . Any 
appropriate sample can be assessed to detect the presence of 
a ZIKV genome , or a portion thereof , and / or the presence of 
one or more ZIKV polypeptides . For example , biological 
samples such as fluid samples ( e.g. , blood ( e.g. , whole 
blood , plasma , and serum ) , urine , breast milk , saliva , amni 
otic fluid , cerebral spinal fluid , or semen ) or tissue samples 
( e.g. , placenta tissue samples ) can be obtained from a 
mammal and assessed for the presence the presence of a 
ZIKV genome , or a portion thereof , and / or the presence of 
one or more ZIKV polypeptides . Any appropriate method 
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can be used to detect the presence the presence of a ZIKV 
genome , or a portion thereof . For example , polymerase 
chain reaction ( PCR ) techniques ) , sequencing techniques , 
and / or Southern blotting can be used to detect the presence 
of a ZIKV genome , or a portion thereof , in a sample obtained 
from a mammal . Any appropriate method can be used to 
detect the presence the presence of one or more ZIKV 
polypeptides . For example , western blotting techniques , 
enzyme - linked immunosorbent assays ( ELISAs ) , and / or 
real - time PCR can be used to detect the presence of one or 
more ZIKV polypeptides in a sample obtained from a 
mammal . 
[ 0028 ] In some cases , methods described herein can 
include identifying a mammal ( e.g. , a human ) as being at 
risk of developing ZIKV viremia ( e.g. , a ZIKV infection ) .
For example , a mammal undergoing , or scheduled to 
undergo , exposure to one or more mammals having ZIKV 
viremia can be at risk of developing ZIKV viremia . In some 
cases , a mammal having physical contact ( e.g. , sexual 
contact ) with one or more mammals having ZIKV viremia 
can be at risk of developing ZIKV viremia ( e.g. , a ZIKV 
infection ) . In some cases , a mammal living in or moving to 
an area where one or more mammals having ZIKV viremia 
are present can be at risk of developing ZIKV viremia ( e.g. , 
a ZIKV infection ) . In some cases , a mammal scheduled to 
travel to an area where one or more mammals having ZIKV 
viremia are present can be at risk of developing ZIKV 
viremia ( e.g. , a ZIKV infection ) . In some cases , a mammal 
that has been bitten , or is at risk of being bitten by an animal 
that carries a ZIKV virus ( e.g. , a mosquito ) can be at risk of 
developing ZIKV viremia ( e.g. , a ZIKV infection ) . In some 
cases , a fetus within a pregnant mammal with ZIKV viremia 
can be at risk of developing ZIKV viremia ( e.g. , a ZIKV 
infection ) 
[ 0029 ] A mammal ( e.g. , a human ) identified as having , or 
as being at risk of developing , ZIKV viremia ( e.g. , a ZIKV 
infection ) , can be administered , or instructed to self - admin 
ister , one or more non - nucleoside RNA polymerase inhibi 
tors . For example , one or more non - nucleoside RNA poly 
merase inhibitors can be administered to a mammal in need 
thereof ( e.g. , a mammal having , or at risk of developing , 
ZIKV viremia ) . A non - nucleoside RNA polymerase inhibi 
tor can be any appropriate non - nucleoside RNA polymerase 
inhibitor . A non - nucleoside RNA polymerase inhibitor can 
be a chemically synthesized non - nucleoside RNA poly 
merase inhibitor . A non - nucleoside RNA polymerase inhibi 
tor can be a commercially obtained non - nucleoside RNA 
polymerase inhibitor . Examples of non - nucleoside RNA 
polymerase inhibitors that can be used as described herein 
( e.g. , to treat a mammal having , or at risk of developing , 
ZIKV viremia ) include , without limitation , non - nucleoside 
RNA polymerase inhibitors shown in FIG . 10 ( e.g. , TPB , 
C1 , C2 , C3 , C4 , C5 , C6 , C7 , C8 , C9 , and C10 ) . In some 
cases , a non - nucleoside RNA polymerase inhibitor can be 
TPB . In cases where a non - nucleoside RNA polymerase 
inhibitor is TPB , the TPB can be a derivative of TPB . As 
used herein , a derivative of a non - nucleoside RNA poly 
merase can be any structurally derived compound that 
maintains the ability to inhibit a non - nucleoside RNA poly 
merase . For example , a mammal having , or at risk of 
developing , ZIKV viremia can be administered or can 
self - administer TPB . 
[ 0030 ] A non - nucleoside RNA polymerase inhibitor ( e.g. , 
TPB ) can inhibit ZIKV replication . In some cases , a non 
nucleoside RNA polymerase inhibitor can inhibit transcrip 
tion of a ZIKV coding sequence ( e.g. , coding sequence 
encoding a ZIKV polymerase such as the RdRp polymerase 
gene ) . In some cases , a non - nucleoside RNA polymerase 
inhibitor can inhibit function of a ZIKV polypeptide ( e.g. , a 
ZIKV polymerase such as the RdRp polymerase ) . For 
example , when a non - nucleoside RNA polymerase inhibitor 
is TPB , the TPB can inhibit function of the RdRp poly 
merase . In some cases , TPB can target ( e.g. , bind to ) a 
catalytic active site of the RdRp polymerase to inhibit ZIKV 
replication . 
[ 0031 ] A non - nucleoside RNA polymerase inhibitor can 
be a potent inhibitor ( e.g. , a potent ZIKV inhibitor ) . For 
example , when a non - nucleoside RNA polymerase inhibitor 
is TPB , the TPB can inhibit a ZIKV ( e.g. , inhibit ZIKV 
replication ) at sub - micromolar concentrations . In some 
cases , the inhibitory concentration 50 ( IC50 ) of TPB can 
from about 10 nM to about 200 nM ( e.g. , from about 10 nM 
to about 175 nM , from about 10 nM to about 150 nM , from 
about 10 nM to about 125 nM , from about 10 nM to about 
100 nM , from about 10 nM to about 75 nM , from about 10 
nM to about 60 nM , from about 10 nM to about 50 nM , from 
about 10 nM to about 40 nM , from about 10 nM to about 30 
nM , from about 10 nM to about 20 nM , from about 25 nM 
to about 200 nM , from about 50 nM to about 200 nM , from 
about 70 nM to about 200 nM , from about 90 nM to about 
200 nM , from about 100 nM to about 200 nM , from about 
125 nM to about 200 nM , from about 150 nM to about 200 
nM , from about 175 nM to about 200 nM , from about 25 nM 
to about 175 nM , from about 50 nM to about 150 nM , from 
about 75 nM to about 125 nM , from about 50 nM to about 
100 nM , from about 100 nM to about 150 nM , from about 
30 nM to about 80 nM , from about 50 nM to about 70 nM , 
or from about 85 nM to about 95 nM ) . For example , the IC50 
of TPB can be about 94 nM . 
[ 0032 ] A non - nucleoside RNA polymerase inhibitor can 
have low toxicity ( e.g. , cellular toxicity or cytotoxicity ) . For 
example , when a non - nucleoside RNA polymerase inhibitor 
is TPB , the TPB can have sub - micromolar cytotoxicity 
concentrations . In some cases , the cellular cytotoxicity con 
centration 50 ( CC50 ) of TPB can be from about 15 uM to 
about 25 uM . For example , the CC50 of TPB can be about 
19.4 uM . 
[ 0033 ] A non - nucleoside RNA polymerase inhibitor can 
have high selectivity ( e.g. , can be selective for a ZIKV ) . A 
selective index 50 ( SI50 ) can be determined using the 
formula CC50 / IC50 . For example , when a non - nucleoside 
RNA polymerase inhibitor is TPB , the TPB can have a high 
SI50 . In some cases , the S150 of TPB can be from about 150 
to about 250. For example , the S150 of TPB can be about 206 . 
[ 0034 ] When treating a mammal having , or at risk of 
developing , ZIKV viremia ( e.g. , a ZIKV infection ) , one or 
more non - nucleoside RNA polymerase inhibitors ( e.g. , 
TPB ) can be administered to the mammal at any appropriate 
time . For example , when a mammal has ZIKV viremia , one 
or more non - nucleoside RNA polymerase inhibitors can be 
administered before , during ( e.g. , concurrent with ) , and / or 
after one or more symptoms of a ZIKV infection are 
producing or showing ( e.g. , after a ZIKV infection has 
developed ) . In some cases , when a mammal has ZIKV 
viremia , one or more non - nucleoside RNA polymerase 
inhibitors can be administered before one or more symptoms 
of a ZIKV infection producing or showing no symptoms 
( e.g. , when the mammal is asymptomatic and / or prior to a 
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ZIKV infection developing ) . For example , when a mammal 
at risk of developing ZIKV viremia ( e.g. , a ZIKV infection ) 
is undergoing , or scheduled to undergo , exposure to one or 
more mammals having ZIKV viremia ( e.g. , a ZIKV infec 
tion ) , one or more non - nucleoside RNA polymerase inhibi 
tors can be administered before , during ( e.g. , concurrent 
with ) , and / or after the exposure . 
[ 0035 ] One or more non - nucleoside RNA polymerase 
inhibitors ( e.g. , TPB ) can be administered to a mammal in 
need thereof ( e.g. , a mammal having , or at risk of develop 
ing , ZIKV viremia ) by any appropriate route . Administration 
can be local or systemic . Examples of routes of administra 
tion include , without limitation , intraperitoneal , intravenous , 
intramuscular , subcutaneous , oral , intranasal , inhalation , 
transdermal , and parenteral administration . For example , 
one or more non - nucleoside RNA polymerase inhibitors can 
be administered intraperitoneally to a mammal ( e.g. , a 
human ) . 
[ 0036 ] When treating a mammal having , or at risk of 
developing , ZIKV viremia ( e.g. , a ZIKV infection ) , the 
treatment can include the administration of a therapeutically 
effective amount of one or more non - nucleoside RNA 
inhibitors . The terms " effective amount ” and “ therapeuti 
cally effective amount ” refer to that amount of one or more 
non - nucleoside RNA inhibitors sufficient to result in a 
therapeutic effect . For example , a therapeutic effect of 
treating a mammal having , or at risk of developing , ZIKV 
viremia can include , without limitation , inhibition of ZIKV 
replication , reduction or elimination of ZIKV viremia , and / 
or amelioration ( e.g. , reduction or elimination ) of one or 
more symptoms of a ZIKV infection . 
[ 0037 ] In some cases , treating a mammal having , or at risk 
of developing , ZIKV viremia ( e.g. , a ZIKV infection ) as 
described herein ( e.g. , by administering one or more non 
nucleoside RNA polymerase inhibitors such as TPB to the 
mammal ) can be effective to inhibit ZIKV replication . For 
example , administering one or more non - nucleoside RNA 
polymerase inhibitors to a mammal can be effective to 
inhibit ZIKV replication within in one or more cells in that 
mammal . Any appropriate method can be used to determine 
whether or not ZIKV replication has been inhibited . For 
example , quantitative RT - PCR ( RT - qPCR ) and / or ELISAS 
can be used to determine whether or not ZIKV replication 
has been inhibited . 
[ 0038 ] In some cases , treating a mammal having , or at risk 
of developing , ZIKV viremia ( e.g. , a ZIKV infection ) as 
described herein ( e.g. , by administering one or more non 
nucleoside RNA polymerase inhibitors such as TPB to the 
mammal ) can be effective to reduce or eliminate ZIKV 
viremia . For example , administering one or more non 
nucleoside RNA polymerase inhibitors to a mammal can be 
effective to reduce ZIKV viremia within that mammal . 
[ 0039 ] In some cases , administering one or more non 
nucleoside RNA polymerase inhibitors to a mammal having 
ZIKV viremia can be effective to reduce ZIKV viremia by 
from about 40 - fold to about 1000 - fold ( e.g. , from about 
50 - fold to about 1000 - fold , from about 80 - fold to about 
1000 - fold , from about 100 - fold to about 1000 - fold , from 
about 300 - fold to about 1000 - fold , from about 500 - fold to 
about 1000 - fold , from about 700 - fold to about 1000 - fold , 
from about 800 - fold to about 1000 - fold , from about 900 
fold to about 1000 - fold , from about 40 - fold to about 900 
fold , from about 40 - fold to about 700 - fold , from about 
40 - fold to about 500 - fold , from about 40 - fold to about 
200 - fold , from about 40 - fold to about 100 - fold , from about 
50 - fold to about 900 - fold , from about 200 - fold to about 
800 - fold , from about 500 - fold to about 700 - fold , from about 
100 - fold to about 400 - fold , from about 300 - fold to about 
600 - fold , from about 400 - fold to about 700 - fold , from about 
500 - fold to about 800 - fold , or from about 600 - fold to about 
900 - fold ) within that mammal . In some cases , administering 
one or more non - nucleoside RNA polymerase inhibitors to 
a mammal having ZIKV viremia can be effective to reduce 
a ZIKV genome copy number within a mammal . In some 
cases , administering one or more non - nucleoside RNA 
polymerase inhibitors to a mammal having ZIKV viremia 
can be effective to reduce PFU of ZIKV virus within a 
mammal . 
[ 0040 ] Any appropriate method can be used to determine 
the presence , absence , or amount of ZIKV in a mammal . For 
example , RT - qPCR can be used to determine the presence , 
absence , or amount of ZIKV in a mammal . 
[ 0041 ] In some cases , treating a mammal having , or at risk 
of developing , ZIKV viremia ( e.g. , a ZIKV infection ) as 
described herein ( e.g. , by administering one or more non 
nucleoside RNA polymerase inhibitors such as TPB to the 
mammal ) can be effective to reduce the severity of the ZIKV 
infection and / or to reduce or eliminate one or more symp 
toms of the ZIKV infection . In some cases , when a mammal 
is a pregnant mammal ( e.g. , a pregnant human ) , one or more 
symptoms can affect the mammal's fetus ( e.g. , in utero ) 
and / or can affect the mammal's child ( e.g. , after birth such 
as a newborn child ) . Examples of symptoms of a ZIKV 
infection can include , without limitation , fever , rash ( e.g. , 
maculopapular rash ) , muscle pain , joint pain , conjunctivitis , 
vomiting , headache , and congenital Zika syndrome ( e.g. , 
including , but not limited to , microcephaly , decreased brain 
tissue , damage to the back of the eye such as scarring and / or 
pigment changes , joints with limited range of motion such as 
clubfoot , and / or too much muscle tone restricting body 
movement soon after birth ) . In some cases , a symptom of 
ZIKV infection can be as described elsewhere ( see , e.g. , 
www.cdc.gov/zika/symptoms/index.html ) . For example , 
treating a pregnant mammal ( e.g. , a pregnant human ) , hav 
ing , or at risk of developing , ZIKV viremia ( e.g. , a ZIKV 
infection ) as described herein ( e.g. , by administering one or 
more non - nucleoside RNA polymerase inhibitors such as 
TPB to the mammal ) can be effective to reduce or eliminate 
microcephaly in the mammal's fetus and / or the mammal's 
child ( e.g. , after birth ) . 
[ 0042 ] In some cases , one or more non - nucleoside RNA 
polymerase inhibitors ( e.g. , TPB ) can be administered to a 
mammal having , or at risk of developing , ZIKV viremia 
( e.g. , a ZIKV infection ) in the absence of any carriers ( e.g. , 
additives , fillers , vehicles , and / or diluents ) . 
[ 0043 ] In some cases , one or more non - nucleoside RNA 
polymerase inhibitors ( e.g. , TPB ) can be formulated into a 
composition ( e.g. , a pharmaceutically acceptable composi 
tion ) for administration to a mammal having , or at risk of 
developing , ZIKV viremia ( e.g. , a ZIKV infection ) . For 
example , one or more non - nucleoside RNA polymerase 
inhibitors can be formulated together with one or more 
pharmaceutically acceptable carriers ( e.g. , additives , fillers , 
vehicles , and / or diluents ) . In some cases , pharmaceutically 
acceptable carrier can be non - naturally occurring . Pharma 
ceutically acceptable carriers that can be used in a pharma 
ceutical composition described herein include , without limi 
tation , dextrose , methanol , dimethyl sulfoxide ( DMSO ) , ion 
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exchangers , alumina , aluminum stearate , lecithin , serum 
proteins , such as human serum albumin , buffer substances 
such as phosphates , glycine , sorbic acid , potassium sorbate , 
partial glyceride mixtures of saturated vegetable fatty acids , 
water , salts or electrolytes , such as protamine sulfate , diso dium hydrogen phosphate , potassium hydrogen phosphate , 
sodium chloride , zinc salts , colloidal silica , magnesium 
trisilicate , polyvinyl pyrrolidone , cellulose - based sub 
stances , polyethylene glycol , sodium carboxymethylcellu 
lose , polyacrylates , waxes , polyethylene - polyoxypropylene 
block polymers , and wool fat . 
[ 0044 ] In some cases , a composition including one or 
more non - nucleoside RNA polymerase inhibitors ( e.g. , 
TPB ) to be administered to a mammal ( e.g. , a human ) in 
need thereof ( e.g. , a mammal having , or at risk of develop 
ing , ZIKV viremia ) can include one or more non - nucleoside 
RNA polymerase inhibitors as the sole active ingredient . For 
example , TPB can be administered to a mammal having , or 
at risk of developing , ZIKV viremia ( e.g. , a ZIKV infection ) 
as the sole active ingredient used to treat the mammal . 
[ 0045 ] In some cases , a composition including one or 
more non - nucleoside RNA polymerase inhibitors ( e.g. , 
TPB ) to be administered to a mammal ( e.g. , a human ) in 
need thereof ( e.g. , a mammal having , or at risk of develop 
ing , ZIKV viremia ) can include one or more non - nucleoside 
RNA polymerase inhibitors together with one or more 
additional active ingredients ( e.g. , active ingredients that can 
be used to treat a mammal having , or at risk of developing , 
ZIKV viremia ) . Examples of additional active ingredients 
that can be used to treat a mammal having , or at risk of 
developing , ZIKV viremia ( e.g. , a ZIKV infection ) that can 
be used to treat a ZIKV infection include , without limitation , 
anti - histamines ( e.g. , chlorphenamine ) , corticosteroids ( e.g. , 
hydrocortisone ) , fever reducers ( e.g. , acetaminophen ) ,
immunosuppressants ( e.g. , mycophenolic acid ) , and anti 
parasitics ( e.g. , ivermectin ) .
[ 0046 ] A composition including one or more non - nucleo 
side RNA polymerase inhibitors ( e.g. , TPB ) can be designed 
for any route of administration . For example , a composition 
including one or more non - nucleoside RNA polymerase 
inhibitors can be designed for parenteral ( e.g. , intraperito 
neal ) administration . Compositions suitable for parenteral 
administration include , without limitation , aqueous and non 
aqueous sterile injection solutions that can contain anti 
oxidants , buffers , bacteriostats , and solutes that render the 
formulation isotonic with the blood of the intended recipi 
ent . For example , a composition including one or more 
non - nucleoside RNA polymerase inhibitors can be designed 
for oral administration . Compositions suitable for oral 
administration include , without limitation , liquids , tablets , 
capsules , pills , powders , gels , and granules . In some cases , 
a composition including one or more non - nucleoside RNA 
polymerase inhibitors can be formulated for oral adminis 
tration . 
[ 0047 ] A composition including one or more non - nucleo 
side RNA polymerase inhibitors ( e.g. , TPB ) can be designed 
for any type of release ( e.g. , release of the one or more 
non - nucleoside RNA polymerase inhibitors from the com 
position ) into the mammal the composition is administered 
to ( e.g. , a mammal having , or at risk of developing , ZIKV 
viremia ) . For example , a composition including one or more 
non - nucleoside RNA polymerase inhibitors can be designed 
for immediate release , slow release , or extended release . 
[ 0048 ] A composition including one or more non - nucleo 
side RNA polymerase inhibitors ( e.g. , TPB ) can be admin 
istered to a mammal ( e.g. , a human ) in need thereof ( e.g. , a 
mammal having , or at risk of developing , ZIKV viremia ) in 
any appropriate dose ( s ) . Effective doses can vary depending 
on the level of ZIKV viremia , the risk of developing ZIKV 
infection , the route of administration , the age and general 
health condition of the mammal , excipient usage , the pos 
sibility of co - usage with other therapeutic treatments such as 
use of other agents , and the judgment of the treating phy 
sician . For example , in cases where a composition includes 
TPB , the composition can include from about 5 mg TPB per 
kilogram ( kg ) body weight of the mammal being treated to 
about 25 mg TPB per kg body weight of the mammal being 
treated ( e.g. , from about 7 mg / kg to about 25 mg / kg , from 
about 10 mg / kg to about 25 mg / kg , from about 12 mg / kg to 
about 25 mg / kg , from about 15 mg / kg to about 25 mg / kg , 
from about 18 mg / kg to about 25 mg / kg , from about 20 
mg / kg to about 25 mg / kg , from about 22 mg / kg to about 25 
mg / kg , from about 5 mg / kg to about 23 mg / kg , from about 
5 mg / kg to about 20 mg / kg , from about 5 mg / kg to about 17 
mg / kg , from about 5 mg / kg to about 15 mg / kg , from about 
5 mg / kg to about 12 mg / kg , from about 5 mg / kg to about 10 
mg / kg , from about 5 mg / kg to about 8 mg / kg , from about 8 
mg / kg to about 22 mg / kg , from about 10 mg / kg to about 20 
mg / kg , from about 12 mg / kg to about 17 mg / kg , from about 
10 mg / kg to about 15 mg / kg , or from about 15 mg / kg to 
about 20 mg / kg TPB ) . In some cases , a composition includ 
ing TPB can include about 25 mg / kg TPB . For example , in 
cases where a composition includes TPB , the composition 
can be effective to achieve from about 100 ng of TPB per 
milliliter ( mL ) plasma in the mammal being treated to about 
1000 ng of TPB per mL plasma in the mammal being treated 
( e.g. , a plasma concentration of from about 200 ng / mL to 
about 1000 ng / mL , from about 250 ng / mL to about 1000 
ng / mL , from about 275 ng / mL to about 1000 ng / mL , from 
about 300 ng / mL to about 1000 ng / mL , from about 350 
ng / mL to about 1000 ng / mL , from about 400 ng / mL to about 
1000 ng / mL , from about 450 ng / mL to about 1000 ng / mL , 
from about 500 ng / mL to about 1000 ng / mL , from about 550 
ng / mL to about 1000 ng / mL , from about 600 ng / mL to about 
1000 ng / mL , from about 650 ng / mL to about 1000 ng / mL , 
from about 700 ng / mL to about 1000 ng / mL , from about 750 
ng / mL to about 1000 ng / mL , from about 800 ng / mL to about 
1000 ng / mL , from about 850 ng / mL to about 1000 ng / mL , 
from about 900 ng / mL to about 1000 ng / mL , from about 100 
ng / mL to about 900 ng / mL , from about 100 ng / mL to about 
800 ng / mL , from about 100 ng / mL to about 700 ng / mL , 
from about 100 ng / mL to about 600 ng / mL , from about 100 
ng / mL to about 500 ng / mL , from about 100 ng / mL to about 
400 ng / mL , from about 100 ng / mL to about 300 ng / mL , 
from about 200 ng / mL to about 900 ng / mL , from about 300 
ng / mL to about 800 ng / mL , from about 400 ng / mL to about 
700 ng / mL , from about 500 ng / mL to about 600 ng / mL , 
from about 200 ng / mL to about 400 ng / mL , from about 400 
ng / mL to about 600 ng / mL , or from about 600 ng / mL to 
about 800 ng / mL TPB ) . In some cases , a composition 
including TPB can achieve a plasma concentration of greater 
than 500 ng / mL TPB ( e.g. , a plasma concentration of about 
550 ng / mL , about 600 ng / mL , about 650 ng / mL , about 700 
ng / mL , about 750 ng / mL , about 800 ng / mL , about 850 
ng / mL , about 900 ng / mL , or about 950 ng / mL TPB ) . An 
effective amount of a composition including one or more 
non - nucleoside RNA polymerase inhibitors can be any 
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amount that reduces the severity and / or reduces or elimi 
nates one or more symptom of a ZIKV infection without 
producing significant toxicity to the mammal . The effective 
amount can remain constant or can be adjusted as a sliding 
scale or variable dose depending on the mammal's response 
to treatment . Various factors can influence the actual effec 
tive amount used for a particular application . For example , 
the frequency of administration , duration of treatment , use 
of multiple treatment agents , route of administration , level 
of ZIKV viremia , severity of the ZIKV infection , and risk of 
developing a ZIKV infection may require an increase or 
decrease in the actual effective amount administered . 
[ 0049 ] A composition including one or more non - nucleo 
side RNA polymerase inhibitors ( e.g. , TPB ) can be admin 
istered to a mammal ( e.g. , a human ) in need thereof ( e.g. , a 
mammal having , or at risk of developing , ZIKV viremia ) in 
any appropriate frequency . The frequency of administration 
can be any frequency that reduces the severity of the ZIKV 
infection and / or reduces or eliminates one or more symp 
toms of the ZIKV infection without producing significant 
toxicity to the mammal . For example , the frequency of 
administration can be from about once a day to about ten 
times a day , from about three times a day to about eight 
times a day , or from about four times a day to about six times 
a day . The frequency of administration can remain constant 
or can be variable during the duration of treatment . As with 
the effective amount , various factors can influence the actual 
frequency of administration used for a particular application . 
For example , the effective amount , duration of treatment , 
use of multiple treatment agents , route of administration , 
level of ZIKV viremia , severity of the ZIKV infection , and 
risk of developing a ZIKV infection may require an increase 
or decrease in administration frequency . 
[ 0050 ] A composition including one or more non - nucleo 
side RNA polymerase inhibitors ( e.g. , TPB ) can be admin 
istered to a mammal ( e.g. , a human ) in need thereof ( e.g. , a 
mammal having , or at risk of developing , ZIKV viremia ) for 
any appropriate duration . An effective duration for admin 
istering a composition including one or more biguanides can 
be any duration that reduces the severity of the ZIKV 
infection and / or reduces or eliminates one or more symp 
toms of the ZIKV infection without producing significant 
toxicity to the mammal . For example , the effective duration 
can vary from several days to several months or years to a 
lifetime . In some cases , the effective duration for the treat 
ment of mammal in need thereof can range in duration from 
about 2 days to about a week . Multiple factors can influence 
the actual effective duration used for a particular treatment . 
For example , an effective duration can vary with the fre 
quency of administration , effective amount , use of multiple 
treatment agents , route of administration , level of ZIKV 
viremia , severity of the ZIKV infection , and risk of devel 
oping a ZIKV infection . 
[ 0051 ] In some cases , methods described herein also can 
include administering to a mammal in need thereof ( e.g. , a 
mammal having , or at risk of developing , ZIKV viremia ) 
one or more additional treatments used to treat a mammal 
having , or at risk or developing , ZIKV viremia ( e.g. , a ZIKV 
infection ) . The one or more additional treatments used to 
treat a ZIKV infection can include any appropriate treat 
ment . In some cases , a ZIKV infection treatment can include 
getting plenty of rest . In some cases , a ZIKV infection 
treatment can include drinking fluids ( e.g. , to prevent dehy 
dration ) . In some cases , a ZIKV infection treatment can 
include not taking aspirin and / or other non - steroidal anti 
inflammatory drugs ( NSAIDS ) . In some cases , a ZIKV 
infection treatment can include administration of one or 
more pharmacotherapies such as antibiotics ( e.g. , metron 
idazole and dexamethasone ) , anti - histamines ( e.g. , chlo 
rphenamine ) , corticosteroids ( e.g. , hydrocortisone ) , and / or 
fever reducers ( e.g. , acetaminophen ) . For example , a mam 
mal having , or at risk of developing , ZIKV viremia ( e.g. , a 
ZIKV infection ) can be administered one or more non 
nucleoside RNA polymerase inhibitors ( e.g. , TPB ) and can 
be administered one or more additional treatments used to 
treat a ZIKV infection . In cases where a mammal having , or 
at risk of developing , ZIKV viremia ( e.g. , a ZIKV infection ) 
is treated with one or more non - nucleoside RNA polymerase 
inhibitors and is treated with one or more additional agents 
used to treat a ZIKV infection , the additional treatment used 
to treat a ZIKV infection can be administered at the same 
time or independently . For example , when administered 
independently , the one or more non - nucleoside RNA poly 
merase inhibitors can be administered first , and the one or 
more additional treatment used to treat a ZIKV infection can 
be administered second , or vice versa . 
[ 0052 ] In certain instances , a course of treatment and the 
severity of one or more symptoms related to the condition 
being treated ( e.g. , a ZIKV infection ) can be monitored . Any 
appropriate method can be used to determine whether or not 
the severity of one or more symptoms is reduced or elimi 
nated . For example , the severity of a ZIKV infection can be 
assessed using any appropriate methods and / or techniques , 
and can be assessed at different time points . For example , 
physical examinations can be used to determine the severity 
of one or more symptoms of a ZIKV infection . 
[ 0053 ] In some cases , one or more non - nucleoside RNA 
polymerase inhibitors ( e.g. , TPB ) can be used to treat a 
mammal having a disease or disorder associated with a 
ZIKV infection . Examples of diseases and disorders asso 
ciated with a ZIKV infection include , without limitation , 
Guillain - Barre syndrome . 
[ 0054 ] In some cases , one or more non - nucleoside RNA 
merase inhibitors ( e.g. , TPB ) can be used to treat 
mammal having , or at risk of developing , one or more 
additional infections caused by a member of the Flaviviridae 
family , which includes Dengue viruses , West Nile viruses , 
yellow fever viruses , and Japanese encephalitis viruses . 
[ 0055 ] This document also provides kits that can be used 
for a variety of applications including , without limitation , 
diagnosing a mammal as having , or as being at risk of 
developing , ZIKV viremia ( e.g. , a ZIKV infection ) ; treating 
a mammal having , or at risk of developing , ZIKV viremia 
( e.g. , a ZIKV infection ) ; and / or preparing a composition 
( e.g. , by combining reagents ) for use in diagnosing and / or 
treating a mammal having , or at risk of developing , ZIKV 
viremia ( e.g. , a ZIKV infection ) . In some cases , a kit 
provided herein can include one or more non - nucleoside 
RNA inhibitors ( e.g. , TPB ) as described herein . For 
example , a kit can include a composition ( e.g. , a pharma 
ceutically acceptable composition ) including one or more 
non - nucleoside RNA inhibitors . For example , a kit can 
include one or more non - nucleoside RNA inhibitors and one 
or more pharmaceutically acceptable carriers ( e.g. , addi 
tives , fillers , vehicles , and / or diluents ) for preparing and / or 
administering a composition ( e.g. , a vaccine composition ) . 
In some cases , a kit provided herein can include reagents 
that can be used to detect ZIKV infections . For example a kit 
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provided herein can be designed as a diagnostic kit . For 
example , a kit provided herein can be designed as a kit to 
monitor treatment of a mammal having , or at risk of devel 
oping , ZIKV viremia ( e.g. , a ZIKV infection ) . For example , 
a kit provided herein can be designed to include reagents that 
can be used to detect the presence of a ZIKV genome , or a 
portion thereof , and / or the presence of one or more ZIKV 
polypeptides in samples ( e.g. , fluid samples such as blood 
and urine ) obtained from a mammal . In some cases , a kit 
provided herein also can include packaging . In some cases , 
a kit provided herein also can include , instructions for use . 
For example , instructions for use can be provided as a 
separate component within the kit and / or printed directly on 
any packaging ( e.g. , packaging for the kit or packaging for 
a component within the kit ) . 
[ 0056 ] The invention will be further described in the 
following examples , which do not limit the scope of the 
invention described in the claims . 
obtained from ATCC . The cells were grown and maintained 
in Dulbecco's modified Eagle's medium ( DMEM ) contain 
ing 10 % heat - inactivated fetal bovine serum ( FBS ) and 
penicillin / streptomycin ( PS ) in humidified chamber with 5 % 
CO2 at 37 ° C. Zika virus strain PRVABC59 and MR766 
were obtained from Barbara Johnson and Brandy Russell at 
the Centers for Disease Control and Prevention , Fort Col 
lins , Colo . , USA . The viruses were passaged once in Vero 
cells to prepare stocks and were stored at -80 ° C. in small 
aliquots . Titers of the stock viruses were determined by 
plaque assay using Vero cells as described elsewhere ( see , 
e.g. , Annamalai et al . , 2017 J. Virol . 91 : e01348-17 ) . 
EXAMPLES 
Example 1 : Discovery of a Non - Nucleoside RNA 
Polymerase Inhibitor for Blocking Zika Virus 
Replication Through in Silico Screening 
Molecular Modeling and in Silico Screening 
[ 0059 ] The ZIKV RdRp structure was modeled based on 
sequence homology using Modeller 9 program ( Webb and 
Sali , 2014 ) . The DENV - 3 RdRp structure ( PDB : 217U ) was 
used as the template . In silico screening was performed 
using Molegro Virtual Docker ( MVD ) ( Molegro ApS , Aar 
hus , Denmark ) . The docking site was defined using a ray 
tracing algorithm . This resulted in a cavity with a volume of 
approximately 1034 cubic Å . A receptor grid was built 
within this cavity with a resolution of 0.2 Å and a radius of 
13 Å from the geometric center of the cavity in the ZIKV 
RdRp model . A 100,000 compound library from Chem 
Bridge ( Chembridge DIVERSetTM Chemical Library , 
ChemBridge Corporation , San Diego , Calif . ) was used for 
this virtual screening . All structural analysis were conducted 
in the Discovery Studio 4.0 ( Biovia , San Diego , Calif . ) . 
Materials and Methods 
Compounds 
[ 0057 ] Ten lead compounds ( Table 1 ) were purchased 
from Hit2Lead Company ( ChemBridge Corporation , San 
Diego , Calif . ) . Each compound was dissolved in dimethyl 
sulfoxide ( DMSO ) to prepare stock solutions of 10 mM and 
1 mM and was stored at -20 ° C. The compound 1 ( cl ) used 
in this research is 3 - chloro - N - [ ( { 4- [ 4- ( 2 - thienylcarbonyl ) 
1 - piperazinyl ] phenyl ) amino ) carbonothioyl ] -1 - benzothio 
phene - 2 - carboxamide ( TPB ) . Based on 1H NMR and LC 
MS ( ELSD , DAD 200-400 nm , MSD APCI positive ) 
analyses by the provider , the compound is 95 % pure . 
Mycophenolic acid ( MPA ) and Ivermectin ( IVM ) were 
purchased from Sigma ( St. Louis , Mo. ) and resuspended in 
DMSO to prepare stock solutions . All the compounds used 
have > 95 % purity . 
Inhibition Assays 
[ 0060 ] Vero cells were seeded in a 96 - well plate with the 
density of 6000 cells per well . In the initial screening study , 
the compound ( 1 uM ) -virus ( 0.1 PFU / cell ) mixture in virus 
growth medium ( VGM ) [ DMEM containing 2 % FBS , PS , 
20 mM hydroxyethyl piperazine ethane sulfonic acid 
( HEPES ) , 1 mM sodium pyruvate , and non - essential amino 
acids ] was added to the cells and incubated for 72 h . In a 
separate experiment conducted using 12 - well plates , the 
cells were first infected with the virus at 0.1 PFU / cell and 
following adsorption , the cells were washed twice in PBS 
and incubated in VGM containing 1 uM concentrations of 
the drugs . The cell culture media were collected at 72-96 h 
post - infection and assayed for infectious virus by plaque 
assay and viral genome copies by quantitative RT - PCR 
( RT - qPCR ) . In all subsequent studies , cells in 12 - well plates 
were infected with ZIKV at MOI of 0.1 PFU / cell and 
following virus adsorption for 1 h at 37 ° C. , VGM contain 
ing various concentrations TPB was added to the cells and 
incubated as above . Clarified supernatants from the infected 
cells were then used to determine infectious virus or genome 
copies as above . 
TABLE 1 
Docking scores of the top 10 compounds . 































ATP - Based Cell Viability Assay 
indicates text missing or illegible when filed 
Cells and Viruses 
[ 0061 ] A modified ATP based cytopathic effect ( CPE ) 
assay was used for this study based on the CPE method for 
anti - DENV drug development described elsewhere ( see , 
e.g. , Che et al . , 2009 Int . J. Clin . Exp . Med . 2 : 363-373 ) . Vero 
cells ( approximately 30,000 per well ) were seeded in a black 
96 - well plate for 24 hours before the experiment . Cell 
monolayers were treated with various concentrations of the 
drugs for 4 days at 37 ° C. The ATP concentration was 
measured following manufacturer's recommendations using 
[ 0058 ] Vero ( Cercopithecus aethiops , CCL - 81 ) , HTR - 8 / 
SVneo human trophoblast ( CRL - 3271 ) , and NTERA - 2 
human embryonal carcinoma ( CRL - 1973 ) cells were 
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Viral Inhibition Test in Mice CellTiter - Glo kit from Promega ( Madison , Wis . ) . Lumines 
cence was recorded using a Veritas Microplate Luminometer 
at 420 nm . The 50 % cytotoxic concentration ( CC50 ) was 
calculated by a non - linear regression analysis of the dose 
response curves . 
[ 0066 ] Balb / C mice were obtained from the Jackson Labo 
ratory ( Bar Harbor , Me . , USA ) . After acclimatization for 
four days , groups of animals ( n = 6 per group ) were injected 
intraperitoneally with 25 mg / kg body weight dose of TPB 
diluted in saline or saline alone ( no drug control ) . Following 
three injections at 12 h intervals , 500 PFU of PRVABC59 
virus diluted in PBS was inoculated into each mouse by the 
subcutaneous ( SC ) route . Blood was collected by retro 
orbital bleeding under anesthesia at days 2 , 3 , 4 , 5 , and 6 
post - infection . Viral genome copies in the plasma were 
determined by RT - PCR . 
Quantitative Real Time RT - PCR 
[ 0062 ] ZIKV viral RNA was detected using RT - qPCR on 
a C100 Thermal Cycler and the CFX96 Real - Time system 
( Bio - Rad ) . Viral RNA ( VRNA ) was extracted from culture 
supernatant using a Q1Aamp Viral RNA Mini kit ( Qiagen ) 
and TaqMan Fast Virus 1 - Step Master Mix ( Life technolo 
gies ) . ZIKV primers and probe ( ZIKF : CCGCTGC 
CCAACACAAG ( SEQ ID NO : 1 ) ; ZIK - R : CCACTAACGT 
TCTTTTGCAGACAT ( SEQ ID NO : 2 ) ; PCR Probe : ZIK - P : 
AGCCTACCTTGACAAGCAATCAGACACTCAA ( SEQ 
ID NO : 3 ) ) were used for quantitative RT - PCR ( RT - qPCR ) 
with the following parameters : 50 ° C. 30 min , 95 ° C. 5 min , 
( 95 ° C. 30 S , 58 ° C. 1 min ) x40 cycles . RNA standard 
concentrations were determined based on the back calcula 
tion with OD values and molecular weights and were 
generated through serial dilution with R2 > 0.95 . 
Statistical Analysis 
[ 0067 ] Data were analyzed using GraphPad Prism soft 
ware version 6.0 . Unpaired two - tailed Student's t - test for 
pairwise comparison between the groups to determine sig 
nificant differences in viral loads ( RNA levels and infectious 
titer ) was performed . Data were represented as 
( SEM ) . 
means 
Results 
Pharmacokinetic ( PK ) Study Design 
[ 0063 ] For PK studies , groups of Balb / C mice ( n = 3 ) were 
injected intraperitoneally with doses of 5 mg / kg or 25 mg / kg 
of body weight of TPB in 5 % dextrose , plasma was collected 
from the animals at various times post - injection and stored 
at -80 ° C. until analysis by LC - MS / MS for TPB concen 
trations . Plasma drug levels were subjected to noncompart 
mental analysis ( WinNonlin ver . 6.4 Certera Inc. , Princeton , 
N.J. ) . The predicted steady - state levels > 500 ng / ml were 
estimated using a twelve h dosing of 25 mg / kg dose of the 
compound in mice . 
Determination of Drug Concentration in Plasma 
[ 0064 ] TPB was dissolved in DMSO at 1 mg / ml . Working 
standard solutions were then prepared in 50 % methanol in 
water from the stock solution . Standards ( an eight - point 
calibration curve ) and quality controls ( at three levels ) were 
prepared by spiking the working standard solutions to blank 
mouse plasma . One hundred ul aliquot of plasma was mixed 
with 25 ul of internal standard spiking solution ( rilpivirine 
1000 ng / ml in 50 % acetonitrile in water ) , 1.5 ml ethyl 
acetate was added and vortexed vigorously for 15 min . The 
tubes were centrifuged at 1700xg for 5 min and 1.3 ml 
supernatant was evaporated to dryness under a stream of 
nitrogen at 40 ° C. The dried extract was reconstituted with 
0.1 ml of 50 % acetonitrile in water and 5 ul was injected into 
the LCMS / MS instrument . The dynamic range of the 
method was 25-4000 ng / ml . 
[ 0065 ] An Agilent 1200 HPLC system ( Agilent Technolo 
gies , CA , USA ) coupled with AB Sciex API 3200 Q Trap 
with an electrospray ionization source ( Applied Biosystems ,
Foster City , Calif . , USA ) was used . The mass transitions m / z 
541.2330.2 and 541.2212.2 for analyte and m / z 367 . 
2195.2 for internal standard were monitored . Chromato 
graphic separation was carried out on Phenomenex Synergi 
Polar - RP ( 150x2.0 mm , 4u ) column with isocratic mobile 
phase consisting of 0.1 % formic acid in water ( A ) and 0.1 % 
formic acid in acetonitrile ( B ) ( 20:80 v / v ) at a flow rate of 
0.5 ml / min . The retention times of analyte and internal 
standard were 2 and 1.2 min respectively . 
In Silico Screening of a Compound Library Against ZIKV 
Polymerase ( RdRp ) Loops 
[ 0068 ] Since the crystal structure of ZIKV RdRp was not 
available when this project was initiated , we generated a 
three - dimensional model of ZIKV RdRp through structural 
modeling based on the analog of DENV - 3 RdRp structure 
( PDB : 2J7U ) . The choice of the DENV - 3 RdRP structure as 
the template was due to its high level of protein sequence 
homology ( 65 % identity and 78 % similarity ) and the high 
resolution ( 1.8 D ) of the structure . The predicted ZIKV 
RdRp structure superimposed closely with a recently solved 
crystal structure ( see , e.g. , Duan et al . , 2017 EMBO J. 
36 : 919-933 ) of ZIKV RdRp ( FIG . 8 ) with C - alpha atom 
RMSD of 2.519 . The target site appears to fit well and the 
relative larger RMSD value should be mainly from the 
flexible loops and the outer layers of the three domains . Like 
RdRp structures in other flaviviruses , the ZIKV RdRp 
structure model showed a very similar right - handed archi 
tecture with fingers , palm and thumb subdomains ( FIG . 1A ) . 
Subsequently , we conducted in silico screening of a library 
of 100,000 small molecule compounds against the catalytic 
active site on the ZIKV RdRp molecule . The active site is in 
the palm subdomain which is critical for de novo RNA 
synthesis performed by ZIKV RdRp . Based on the in silico 
screening data , the top 10 compounds with highest docking 
scores are shown in Table 1. The molecular weights of these 
compounds are also similar ( around 500 Da ) which are in the 
appropriate range of druggable compounds . 
Cell - Based Inhibition Test of the Lead Compounds Against 
ZIKV Infection 
[ 0069 ] Examination of PRVABC59 ZIKV growth in Vero 
cells in the presence of 1 uM concentrations of the com 
pounds ( cl - c10 ) showed that cl , 3 - chloro - N - [ ( { 4- [ 4- ( 2 
thienylcarbonyl ) -1 - piperazinyl ] phenyl } amino carbonoth 
ioyl ] -1 - benzothiophene - 2 - carboxamide ( TPB , FIG . 1B ) , 
exhibited the highest inhibitory activity among the 10 lead 
compounds tested . While the ZIKV growth was inhibited ( as 
determined by genome copies in the culture supernatants ) by 
> 99 % in cells treated with TPB compared to the vehicle 
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only treated cells ( FIG . 2A ) , c . and c10 also inhibited virus 
growth by nearly 70-80 % . Infectious virus yield was inhib 
ited by at least 1000 - fold in the presence of 1 uM cl ( FIG . 
2B ) whereas c6 and c10 inhibited the yield by nearly 10 - fold 
at the same concentrations . Although the majority of the 
compounds could be readily seen bound to the target site , cl , 
c6 , and c10 appeared to have made additional contacts with 
the priming loop as well as other regions in the RdRp target 
site ( FIG . 9 ) . From molecular docking analysis , it appears 
that cl interacts with residues in the target site of the viral 
RdRp ( FIG . 1C - D ) . Three hydrogen bonds of TPB are in 
direct contact with two aspartic acid residues ( D535 in motif 
A and D665 in motif C ) in RdRp ( FIG . 1C ) . Since these two 
aspartic acid residues as well as D665 are highly conserved 
residues in the target and active site of all RdRps of 
flaviviruses and play critical roles in coordinating divalent 
metal ions ( Mg ++ ) , TPB could potentially be a highly 
promising anti - ZIKV as well as anti - flavivirus drug candi 
date . So , from the initial cursory screening studies , TPB was 
shown to inhibit ZIKV replication significantly . 
[ 0070 ] We then tested the inhibitory activity of TPB in a 
dose - dependent manner in the uM range . The results show 
that even at 0.5 um concentration of TPB , significant 
inhibitory activity against ZIKV replication was observed . 
Both genome copy numbers ( FIG . 3A ) and infectious virus 
( FIG . 3B ) in the supernatants were reduced by over 100 - fold 
at this concentration of TPB . Although TPB at 1 uM reduced 
virus growth by over 1000 - fold , further increase in TPB 
concentration did not result in further inhibition ( FIG . 
3A - B ) . Viral E protein synthesis in infected cells was also 
significantly inhibited at 0.5 UM TPB and was undetectable 
at higher concentrations ( FIG . 3C ) . These results suggest 
that TPB is a potent inhibitor of ZIKV replication . 
the Vero cells infected with PRVABC59 . The culture super 
natants were assayed for infectious virus by plaque assay 
and expressed as % virus yield relative to the virus yield 
without TPB . The data were statistically analyzed and the 
IC50 concentration was determined to be about 94 nM ( FIG . 
5A ) . The IC50 value of TPB in the 10-100 nM range also 
suggests that TPB is a strong inhibitor of ZIKV and a 
potential drug candidate for further development . 
[ 0074 ] Cellular Cytotoxicity 50 ( CC50 ) Determination . 
[ 0075 ] Low level of cellular cytotoxicity is an essential 
criterion for drug development . It also suggests whether the 
drug's inhibitory effect is independent of cellular cytotox 
icity due to the presence of the drug . Therefore , we con 
ducted cell viability assay to determine the cellular cytotox 
icity 50 ( CC50 ) concentration of TPB . Our results show that 
CC50 of TPB is 19.4 UM ( FIG . 5B ) . The selectivity index 50 
( S150 , CC50 / IC50 ) is calculated to be 206. This high S150 
also suggests that TBP is not only a potent inhibitor of ZIKV 
at sub - micromolar concentrations but is also nontoxic to the 
cells . 
[ 0076 ] Comparison of TPB Inhibition with Other Known 
Inhibitors of ZIKV . 
[ 0077 ] To further compare the potency of TPB relative to 
other identified ZIKV inhibitors , two inhibitors were exam 
ined that have been recently shown to inhibit ZIKV repli 
cation . Mycophenolic acid ( MPA ) is an immunosuppressant 
drug used to prevent rejection in organ transplantation and 
was shown to inhibit DENV RNA replication ( see , e.g. , 
Diamond et al . , 2002 Virology 304 : 211-221 ) . In a screen of 
FDA - approved drugs for inhibition of ZIKV infection , MPA 
at 1 uM was found to inhibit infection of cells in vitro by 
ZIKV by over 99 % ( see , e.g. , Barrows et al . , 2016 Cell Host 
Microbe 20 : 259-270 ) . Likewise , Ivermectin ( IVM ) , an anti 
parasitic drug was found to inhibit ZIKV infection strongly 
at 10 uM ( see , e.g. , Barrows et al . , 2016 Cell Host Microbe 
20 : 259-270 ) . A side - by - side comparison of the inhibitory 
potency of TPB with MPA and IVM shows that while TPB 
inhibited ZIKV yield by over 1000 - fold , MPA and IVM 
inhibited virus yield by approximately 10- to 20 - fold ( FIG . 
6 ) . These results suggest that TPB is more potent in inhib 
iting ZIKV as compared to MPA or IVM . 
ZIKV Growth Inhibition of by TPB 
[ 0071 ] Since we used the contemporary isolate of ZIKV 
( PRVABC59 , isolated from a patient in Puerto Rico in 2015 ) 
in our initial studies , we wanted to determine if TBP also has 
antiviral activity against the historical isolate of the virus . 
Our results suggest that the MR766 Ugandan isolate was 
also sensitive to inhibition by TPB at the concentrations 
tested ( FIG . 4A ) . The extent of MR766 virus growth inhi 
bition appeared to be similar to that of the PRVABC59 virus 
( FIGS . 3 and 4A ) . Overall , it appears that maximal ZIKV 
growth inhibition by TPB could be achieved at 1 or 2 uM 
concentrations and further increase had no significant inhibi 
tory effect , indicating that the TPB inhibitory target is 
saturable at these concentrations . In addition , not only TPB 
inhibited ZIKV growth in Vero cells ( FIG . 3 ) , but also it 
inhibited the virus growth in other cells such as human 
trophoblast cell line HTR - 8 ( FIG . 4B ) as well as the human 
testicular cell line NTERRA ( FIG . 4C ) that are known to be 
the targets of ZIKV infection in humans . Overall , these 
studies suggest that TBP inhibits both the contemporary and 
historical isolates of the virus and that the inhibition is not 
cell - type dependent . 
Antiviral Activity of TPB In Vivo 
[ 0078 ] Since TPB was found to be a potent inhibitor of 
ZIKV replication in vitro , we wanted to examine if it also 
inhibits virus replication and viremia in an immunocompe 
tent mouse model . Therefore , a pharmacokinetics ( PK ) 
analysis of TPB in immunocompetent Balb / C mice was 
conducted to examine the stability and in vivo retention of 
the drug . The results of PK studies suggest that TPB is 
retained in the mouse plasma at approximately 100 ng / ml 
level 10-12 h post - injection at the two doses tested ( FIG . 
7A ) . Based on non - compartment analysis of the data , it was 
estimated that steady - state levels > 500 ng / ml of TPB ( ~ 1 
UM ) could be achieved using a twelve hour dosing at 25 
mg / kg dose of the compound in mice . To examine the effect 
of the drug on ZIKV growth in mice , groups of mice ( n = 6 ) 
were injected with the drug at 25 mg / kg dose and subse 
quently infected with 500 PFU of ZIKV . Virus load in the 
plasma of the animals at 24 hour intervals was determined . 
Results of virus growth ( genome copies ) in individual 
animals ( FIG . 7B ) show that these immunocompetent mice 
supported transient ZIKV growth and the level of viral RNA 
detected on day 4 post - infection was nearly 40 - fold lower in 
Characterization of TPB Antiviral Activity In Vitro : IC50 
and CC50 
[ 0072 ] Inhibitory Concentration 50 ( IC50 ) Determination . 
[ 0073 ] To characterize the anti - ZIKV potency of TPB , we 
conducted studies to determine the inhibitory concentration 
50 ( IC50 ) . We used serial 2 - fold dilutions of TPB and treated 
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mice injected with the drug as compared to the group 
injected with the vehicle ( 5 % dextrose ) alone ( FIG . 7C ) . The 
level of TPB in the plasma on average reached nearly 270 
ng / ml by 2 days post - infection ( FIG . 7D ) . Although this 
level of TPB was not optimal for maximal virus growth 
inhibition as observed under in vitro conditions , the results 
suggest that TPB exerts significant growth inhibition of 
ZIKV in vivo . 
4. The method of claim 1 , wherein said non - nucleoside 
RNA polymerase inhibitor is 3 - chloro - N - [ { { 4- [ 4- ( 2 - thienyl 
carbonyl ) -1 - piperazinyl ] phenyl } amino ) carbonothioyl ] -1 
benzothiophene - 2 - carboxamide ( TPB ) . 
5. The method of claim 1 , wherein said non - nucleoside 
RNA polymerase inhibitor has an inhibitory concentration 
50 ( IC50 ) of from about 10 nM to about 200 nM . 
6. The method of claim 1 , wherein said non - nucleoside 
RNA polymerase inhibitor has a cytotoxicity concentration 
50 ( CC50 ) of from about 15 uM to about 25 uM . 
7. The method of claim 1 , wherein said non - nucleoside 
RNA polymerase inhibitor has a selective index 50 ( SI50 ) of 
about 206 . 
8. The method of claim 1 , wherein said administering step 
is performed prior to said ZIKV infection or after said ZIKV 
infection . 
OTHER EMBODIMENTS 
[ 0079 ] It is to be understood that while the invention has 
been described in conjunction with the detailed description 
thereof , the foregoing description is intended to illustrate 
and not limit the scope of the invention , which is defined by 
the scope of the appended claims . Other aspects , advantages , 
and modifications are within the scope of the following 
claims . 
SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 3 
< 210 > SEQ ID NO 1 
< 211 > LENGTH : 17 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic primer 
< 400 > SEQUENCE : 1 
ccgctgccca acacaag 17 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 24 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic primer 
< 400 > SEQUENCE : 2 
ccactaacgt tcttttgcag acat 24 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 31 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : synthetic probe 
< 400 > SEQUENCE : 3 
agcctacctt gacaagcaat cagacactca a 31 
What is claimed is : 
1. A method for treating a mammal having a Zika virus 
( ZIKV ) infection , said method comprising : administering to 
said mammal a composition comprising a non - nucleoside 
RNA polymerase inhibitor . 
2. The method of claim 1 , wherein said mammal is a 
human . 
3. The method of claim 1 , wherein said non - nucleoside 
RNA polymerase inhibitor can bind to a catalytic active site 
of an RNA - dependent RNA - polymerase ( RdRp ) of said 
ZIKV to inhibit ZIKV replication . 
9. The method of claim 1 , wherein said administering step 
is performed prior to said ZIKV infection and after infection 
said ZIKV infection . 
10. The method of claim 1 , wherein said non - nucleoside 
RNA polymerase inhibitor is administered intraperitoneally , 
intravenously , intramuscularly , or subcutaneously . 
11. A method of preventing microcephaly in a fetus said method comprising : administering a composition compris 
ing a non - nucleoside RNA polymerase inhibitor to a mam 
mal pregnant with said fetus , wherein said mammal has a 
ZIKV infection . 
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12. The method of claim 11 , wherein said mammal is a 
human . 
13. The method of claim 11 , wherein said non - nucleoside 
RNA polymerase inhibitor is 3 - chloro - N - [ ( { 4- [ 4- ( 2 - thienyl 
carbonyl ) -1 - piperazinyl ] phenyl } amino ) carbonothioyl ] -1 
benzothiophene - 2 - carboxamide ( TPB ) . 
14. A method of treating an adult mammal having Guil 
lain - Barre syndrome said method comprising : administering 
to said mammal a composition comprising a non - nucleoside 
RNA polymerase inhibitor , wherein said mammal has a 
ZIKV infection . 
15. The method of claim 14 , wherein said mammal is a 
human . 
16. The method of claim 14 , wherein said non - nucleoside 
RNA polymerase inhibitor is 3 - chloro - N - [ ( { 4- [ 4- ( 2 - thienyl 
carbonyl ) -1 - piperazinyl ] phenyl } amino ) carbonothioyl ] -1 
benzothiophene - 2 - carboxamide ( TPB ) . 
